M
Muhammad Umer Ashraf
Researcher at Sungkyunkwan University
Publications - 10
Citations - 127
Muhammad Umer Ashraf is an academic researcher from Sungkyunkwan University. The author has contributed to research in topics: Efficient energy use & Haematopoiesis. The author has an hindex of 4, co-authored 10 publications receiving 55 citations.
Papers
More filters
Journal ArticleDOI
Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.
TL;DR: An improved understanding of DC-mediated Th2 immunity and Th1/Th2 immune balancing is provided, leading to control over their adverse consequences.
Journal ArticleDOI
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform.
TL;DR: In this paper, the authors summarized the immune-based strategies for the development of COVID-19 vaccines and the different vaccine candidate platforms that are in clinical stages of evaluation, and up to the recently licensed mRNA-based COVID19 vaccines of Pfizer-BioNtech and Moderna's.
Journal ArticleDOI
Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia.
TL;DR: In this article, the therapeutic potential of m6A-modifiers in controlling haematological disorders, especially acute myeloid leukaemia (AML), was summarized.
Journal ArticleDOI
Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH.
Sunil Kumar,Parth Sarthi,Indra Mani,Muhammad Umer Ashraf,Myeong-Ho Kang,Vishal Kumar,Yong-Soo Bae +6 more
TL;DR: In this article, the authors proposed to improve the efficacy of ICB-therapy by co-targeting molecular checkpoints especially N6A-modification machineries which can be reformed into RNA modifying drugs (RMD).
Journal ArticleDOI
Therapeutic Potential of microRNA Against Th2-associated Immune Disorders.
TL;DR: In this article, a systemic review aims to summarize the current understanding regarding the role of miRNAs associated with Th2-mediated immune disorders and strategies for therapeutic drug development and current clinical trials.